Published in Circ Res on August 01, 1966
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man. Br Med J (1970) 3.80
The assessment of beta-adrenoceptor blocking drugs in man. Br J Clin Pharmacol (1977) 3.13
Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest (1980) 2.40
New approach to assessment of cardioselectivity of beta-blocking drugs. Br Med J (1974) 2.06
Heart rate variability and autonomic activity at rest and during exercise in various physiological conditions. Eur J Appl Physiol (2003) 1.87
Problems in assessing beta-adrenoceptor antagonism in man. Br J Clin Pharmacol (1975) 1.54
Autonomic blockade by propranolol and atropine to study intrinsic myocardial function in man. J Clin Invest (1969) 1.52
Interaction between isoprenaline and aminophylline in asthma. Thorax (1977) 1.52
Autonomic mechanisms in hemodynamic responses to isometric exercise. J Clin Invest (1974) 1.51
Effect of M & B 17803A, a new -adrenoceptor blocking agent, on the cardiovascular responses to tilting and to isoprenaline in man. Br J Pharmacol (1971) 1.48
Different effects of adrenergic beta-receptor blockade on heart rate response to mental stress, catecholamines, and exercise. Br Med J (1973) 1.36
Use of the systolic time intervals in clinical pharmacology. Br J Clin Pharmacol (1978) 1.33
Autonomic dysfunction in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry (1981) 1.32
Baroreflex sensitivity and responses to the Valsalva manoeuvre in subjects with diabetes mellitus. J Neurol Neurosurg Psychiatry (1976) 1.31
Regulation of increased blood flow (hyperemia) to muscles during exercise: a hierarchy of competing physiological needs. Physiol Rev (2015) 1.19
Cardiovascular effects of alinidine and propranolol alone and in combination with hydralazine in normal man. Br J Clin Pharmacol (1983) 1.16
Autonomic nervous system influence on arterial baroreflex control of heart rate during exercise in humans. J Physiol (2005) 1.12
Attenuated exercise induced hyperaemia with age: mechanistic insight from passive limb movement. J Physiol (2010) 1.08
Role of the venous system in baroreceptor-mediated reflexes in man. J Clin Invest (1968) 1.07
Bronchial and cardiac beta-adrenoceptor blockade--a comparison of atenolol, acebutolol and labetalol. Br J Clin Pharmacol (1981) 1.06
Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. Br J Clin Pharmacol (1979) 1.05
Autonomic neural control of heart rate during dynamic exercise: revisited. J Physiol (2014) 1.01
Phonocardiographic method of assessing changes in left ventricular function after Starr-Edwards replacement of aortic valve. Br Heart J (1970) 1.00
Role of central command in carotid baroreflex resetting in humans during static exercise. J Physiol (2002) 0.97
Time-frequency analysis of heart rate variability during immediate recovery from low and high intensity exercise. Eur J Appl Physiol (2007) 0.96
Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise. Br J Clin Pharmacol (1977) 0.95
Onset and duration of beta-adrenergic receptor blockade following single oral dose acebutolol hydrochloride (Sectral). Br J Clin Pharmacol (1979) 0.95
Neural regulation of cardiovascular response to exercise: role of central command and peripheral afferents. Biomed Res Int (2014) 0.95
Spectral methods of heart rate variability analysis during dynamic exercise. Clin Auton Res (2009) 0.93
Abnormal cardiovascular and catecholamine responses to supine exercise in human subjects with sympathetic dysfunction. J Physiol (1995) 0.92
Changes in the baroreceptor reflex at the start of muscle contraction in the decerebrate cat. J Physiol (1991) 0.92
Impact of the exercise mode on heart rate recovery after maximal exercise. Eur J Appl Physiol (2008) 0.92
Influence of ageing on carotid baroreflex peak response latency in humans. J Physiol (2009) 0.90
Alternative to ganglionic blockade with anticholinergic and alpha-2 receptor agents. Clin Auton Res (2006) 0.87
Effects of sustained isometric handgrip on praecordial accelerocardiogram in normal subjects and in patients with heart disease. Br Heart J (1975) 0.86
Changes in cerebral blood flow during steady-state cycling exercise: a study using oxygen-15-labeled water with PET. J Cereb Blood Flow Metab (2013) 0.85
Effects of fitness and age on the response to vagotonic atropine. Auton Neurosci (2008) 0.85
Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise. Eur J Appl Physiol (2008) 0.85
Heart rate variability and circulating catecholamine concentrations during steady state exercise in healthy volunteers. Br Heart J (1993) 0.85
Both central command and exercise pressor reflex activate cardiac sympathetic nerve activity in decerebrate cats. Am J Physiol Heart Circ Physiol (2009) 0.85
Resting autonomic modulations and the heart rate response to exercise. Clin Auton Res (2010) 0.84
Respiration and heart rate complexity: effects of age and gender assessed by band-limited transfer entropy. Respir Physiol Neurobiol (2013) 0.84
The roles of testosterone and alpha-amylase in exercise-induced sexual arousal in women. J Sex Med (2008) 0.83
The effects of raising alveolar PCO2 and ventilation separately and together on the sensitivity and setting of the baroreceptor cardiodepressor reflex in man. J Physiol (1974) 0.82
Are There Deleterious Cardiac Effects of Acute and Chronic Endurance Exercise? Physiol Rev (2016) 0.82
Effect of muscle metaboreflex activation on spontaneous cardiac baroreflex sensitivity during exercise in humans. J Physiol (2011) 0.81
Cardiac and vasomotor components of the carotid baroreflex control of arterial blood pressure during isometric exercise in humans. J Physiol (2006) 0.81
A theory on heart rate control by muscular metabolic receptors. Arch Kreislaufforsch (1971) 0.81
Controlled-release metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline. Eur J Clin Pharmacol (1988) 0.80
Characterisation of heart rate response to exercise in the sick sinus syndrome. Br Heart J (1978) 0.80
Assessment of ventilatory thresholds during graded and maximal exercise test using time varying analysis of respiratory sinus arrhythmia. Br J Sports Med (2005) 0.79
Analysis of physiological signals for recognition of boredom, pain, and surprise emotions. J Physiol Anthropol (2015) 0.79
Diminazene aceturate improves autonomic modulation in pulmonary hypertension. Eur J Pharmacol (2013) 0.78
Concentration-effect relationships for oxprenolol in patients with essential hypertension. Br J Clin Pharmacol (1988) 0.78
Heart Rate Dynamics after Exercise in Cardiac Patients with and without Type 2 Diabetes. Front Physiol (2011) 0.78
Dynamic cardiac output regulation at rest, during exercise, and muscle metaboreflex activation: impact of congestive heart failure. Am J Physiol Regul Integr Comp Physiol (2012) 0.78
A Model of the Cardiorespiratory Response to Aerobic Exercise in Healthy and Heart Failure Conditions. Front Physiol (2016) 0.77
Does respiratory sinus arrhythmia serve a buffering role for diastolic pressure fluctuations? Am J Physiol Heart Circ Physiol (2010) 0.77
Muscle sympathetic nerve activity at rest compared to exercise tolerance. Eur J Appl Physiol (2007) 0.77
Reproducibility of exercise-induced modulation of cardiovascular responses to cold stress. Clin Auton Res (1997) 0.77
The effect of functional overreaching on parameters of autonomic heart rate regulation. Eur J Appl Physiol (2017) 0.77
Submaximal exercise intensity modulates acute post-exercise heart rate variability. Eur J Appl Physiol (2016) 0.76
Thoracolumbar spinal manipulation and the immediate impact on exercise performance. J Chiropr Med (2012) 0.76
QT-RR hysteresis is caused by differential autonomic states during exercise and recovery. Am J Physiol Heart Circ Physiol (2012) 0.76
Energy expenditure of genuine laughter. Int J Obes (Lond) (2006) 0.76
MicroRNA regulation in heart and skeletal muscle over the freeze-thaw cycle in the freeze tolerant wood frog. J Comp Physiol B (2015) 0.76
Baroreflex sensitivity and neurohormonal activation in patients with acute myocardial infarction. Br Heart J (1995) 0.76
Changes in spectral indices of heart rate variability during exercise in acute myocardial infarction. Korean J Intern Med (1993) 0.75
The Prevalence of Clinical and Electrocardiographic Risk Factors of Cardiovascular Death Among On-duty Professional Firefighters. J Cardiovasc Nurs (2015) 0.75
4-Second Exercise Test: Reference Values for Ages 18-81 Years. Arq Bras Cardiol (2015) 0.75
Chronotropic incompetence can limit exercise tolerance in COPD patients with lung hyperinflation. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Ro 3-4787, a new β-adrenoceptor blocking agent: Studies in normal volunteers. Br J Clin Pharmacol (1974) 0.75
Beta-adrenoceptor antagonists and respiratory function. Br J Clin Pharmacol (1978) 0.75
Supine effect of passive cycling movement induces vagal withdrawal. J Phys Ther Sci (2015) 0.75
Impact of cancer and chemotherapy on autonomic nervous system function and cardiovascular reactivity in young adults with cancer: a case-controlled feasibility study. BMC Cancer (2015) 0.75
The assessment of β-adrenoceptor blocking drugs in hyperthyroidism. Br J Clin Pharmacol (1974) 0.75
The effect of acebutolol on tachycardia and performance during competition rifle shooting. Br J Clin Pharmacol (1976) 0.75
Observations on the effect of β-adrenoceptor blocking drugs on glyceryl trinitrate tachycardia. Br J Clin Pharmacol (1974) 0.75
Effects of gravitational acceleration on cardiovascular autonomic control in resting humans. Eur J Appl Physiol (2015) 0.75
Heart rate is associated with mortality in patients undergoing continuous renal replacement therapy. Kidney Res Clin Pract (2017) 0.75
Cardiac Autonomic Responses during Exercise and Post-exercise Recovery Using Heart Rate Variability and Systolic Time Intervals-A Review. Front Physiol (2017) 0.75
Maximal rate of heart rate increase correlates with fatigue/recovery status in female cyclists. Eur J Appl Physiol (2017) 0.75
Effects of gratitude meditation on neural network functional connectivity and brain-heart coupling. Sci Rep (2017) 0.75
The effects of beta1-adrenergic blockade on cardiovascular oxygen flow in normoxic and hypoxic humans at exercise. Eur J Appl Physiol (2005) 0.75
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 12.86
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31
Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med (1996) 6.92
Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res (2004) 6.49
Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation (2004) 6.43
Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med (1990) 5.91
The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation (1982) 5.56
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation (2000) 5.15
Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science (1994) 4.94
TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation (1996) 4.41
Myocardial infarct size and ventricular function in rats. Circ Res (1979) 4.33
Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest (1965) 4.23
Myocardial reperfusion: a double-edged sword? J Clin Invest (1985) 4.12
A trial of two strategies to modify the test-ordering behavior of medical residents. N Engl J Med (1980) 3.98
Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris. Circulation (1967) 3.92
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. Circulation (1968) 3.82
Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med (1991) 3.80
Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol (1971) 3.68
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Aortic stenosis. Circulation (1968) 3.49
Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med (1996) 3.40
Asymmetric septal hypertrophy. Echocardiographic identification of the pathognomonic anatomic abnormality of IHSS. Circulation (1973) 3.31
Colitis cystica profunda. Am J Clin Pathol (1966) 3.28
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26
Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med (1971) 3.24
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (2009) 3.13
Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet (2001) 3.07
Sudden death in young athletes. Circulation (1980) 3.05
Mechanism of action of calcium-channel-blocking agents. N Engl J Med (1982) 2.99
Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med (1988) 2.98
Real-time radionuclide cineangiography in the noninvasive evaluation of global and regional left ventricular function at rest and during exercise in patients with coronary-artery disease. N Engl J Med (1977) 2.94
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation (2000) 2.93
Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med (1987) 2.88
A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet (2001) 2.78
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med (1992) 2.72
Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation (1997) 2.64
Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol (2000) 2.61
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59
Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation (1989) 2.56
"Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol (1988) 2.53
Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest (1967) 2.51
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 2.47
A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med (1989) 2.45
LIM-kinase1 hemizygosity implicated in impaired visuospatial constructive cognition. Cell (1996) 2.44
Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol (1991) 2.40
Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol (1981) 2.37
Unstable angina: an etiologic approach to management. Circulation (1998) 2.31
Causes of sudden death in competitive athletes. J Am Coll Cardiol (1986) 2.31
The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation (1965) 2.30
Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol (1968) 2.29
Coronary-artery surgery at the crossroads. N Engl J Med (1977) 2.28
Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J (2001) 2.28
Comparative left ventricular dimensions in trained athletes. Ann Intern Med (1975) 2.27
Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res (1985) 2.23
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med (1998) 2.22
Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol (2001) 2.22
Coronary-artery spasm. N Engl J Med (1978) 2.20
Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med (1980) 2.20
Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol (1986) 2.20
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med (1980) 2.19
Precordial S-T segment elevation mapping: an atraumatic method for assessing alterations in the extent of myocardial ischemic injury. The effects of pharmacologic and hemodynamic interventions. Am J Cardiol (1972) 2.19
Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol (1986) 2.18
Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med (1987) 2.18
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation (1999) 2.16
Assessment of cardiac contractility. The relation between the rate of pressure rise and ventricular pressure during isovolumic systole. Circulation (1971) 2.15
Velocity of contraction as a determinant of myocardial oxygen consumption. Am J Physiol (1965) 2.11
Mechanism of action of beta-adrenergic receptor blocking agents in angina pectoris: comparison of action of propranolol with dexpropranolol and practolol. Br Med J (1969) 2.11
Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation (1972) 2.10
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Ann Intern Med (1980) 2.08
Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation (1976) 2.08
Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA (2001) 2.07
Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol (2000) 2.05
Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A. Br J Pharmacol (1972) 2.03
Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med (1978) 2.03
Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation (2000) 2.01
Impaired left ventricular diastolic filling in patients with coronary artery disease: assessment with radionuclide angiography. Circulation (1981) 2.00
Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA (1996) 1.99
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J (2002) 1.98
Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation (1994) 1.98
Modification of myocardial infarction size after coronary occlusion. Ann Intern Med (1973) 1.98
The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation (1966) 1.97
Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med (1981) 1.97
Familial prevalence and genetic transmission of idiopathic hypertrophic subaortic stenosis. N Engl J Med (1973) 1.96